23andMe Holding Co. (ME)
NASDAQ (CM) NASDAQ (CM) Primary 
Barrack, Rodos & Bacine Is Investigating 23andMe Holding Co.
PHILADELPHIA, PA / ACCESSWIRE / September 23, 2024 / The law firm of Barrack, Rodos & Bacine is investigating 23andMe Holding Co. (NASDAQ:ME) regarding the mass resignation of all of the independent members of the board of directors following the presentation of an offer by the CEO and co-founder, Anne Wojcicki, to acquire the remaining shares of the company not currently owned by her or her affiliates for a mere 40 cents per share. WHAT'S THIS ABOUT?
ME INVESTIGATION ALERT: 23andMe Holding Co. Shareholders are Alerted to Contact BFA Law regarding Ongoing Investigation into the Company (Nasdaq:ME)
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki ("Wojcicki") of 23andMe breached their fiduciary duties in connection with Wojcicki's ongoing effort to purchase all 23andMe shares she does not already own. If you are a holder of 23andMe, you are encouraged to submit your information at: Click Here
23andMe directors resign as the CEO of the genetic-testing company seeks to take it private
All of 23andMe's independent directors resigned from its board this week, a rare move that marks the latest challenge for the genetic-testing company.
ME STOCK NOTICE: An Investigation has been Initiated Against 23andMe Holding Co. for Breaches of Fiduciary Duties – Shareholders are Urged to Contact BFA Law
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki ("Wojcicki") of 23andMe breached their fiduciary duties in connection with Wojcicki's ongoing effort to purchase all 23andMe shares she does not already own. If you are a holder of 23andMe, you are encouraged to submit your information at: Click Here
How 23andMe Went From Market Darling to Losing Its Entire Board
The genetic-testing company's entire board resigned in protest of its CEO's buy-out offer.
All 23andMe board members but CEO resign over no adequate buyout offers
The board has rejected both of Anne Wojcicki's buyout proposals to save the struggling genetics company
23andMe board resigns in feud over CEO Anne Wojcicki's plan to take company private
The board resignations followed CEO Anne Wojcicki's latest proposal to take the company private.
23andMe's stock tumbles 7% after independent directors quit in clash with CEO over buyout plan
The directors said the decision comes after months of work that failed to result in an actionable plan that meets the interests of non-affiliated shareholders.
23andMe sees independent board directors quit en masse
23andMe, the personal genomics company, went public in early 2021 via a merger with a blank check company that valued it at $3.5 billion. Then its fortunes began to sink.
23andMe CEO Anne Wojcicki 'surprised and disappointed' by board resignations: Read the memo
All seven independent directors resigned from 23andMe's board Tuesday, effective immediately. The directors had formed a special committee in March tasked with helping the struggling company find a new path forward.
23andMe independent directors quit board over unsatisfactory buyout plan from CEO
The independent directors of genetic testing firm 23andMe said on Tuesday they have resigned from the company's board after not receiving a satisfactory take-private offer from CEO Anne Wojcicki.
23andMe Reportedly Paying $30 Million to Settle Data Breach Suit
23andMe will reportedly pay $30 million to settle a lawsuit tied to a data breach. As Reuters reported Friday (Sept.
